Intratumoral CD4+ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer

[1]  Elisabeth F. Heuston,et al.  Single-Cell RNA-Seq Reveals TOX as a Key Regulator of CD8+ T cell Persistence in Chronic Infection , 2019, Nature Immunology.

[2]  A. Chinnaiyan,et al.  CD8+ T cells regulate tumor ferroptosis during cancer immunotherapy , 2019, Nature.

[3]  M. Ceccarelli,et al.  RNA-Seq Signatures Normalized by mRNA Abundance Allow Absolute Deconvolution of Human Immune Cell Types , 2019, Cell reports.

[4]  J. Ahn,et al.  The First-week Proliferative Response of Peripheral Blood PD-1+CD8+ T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors , 2019, Clinical Cancer Research.

[5]  Fabian J Theis,et al.  A test metric for assessing single-cell RNA-seq batch correction , 2018, Nature Methods.

[6]  A. Butte,et al.  Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage , 2018, Nature Immunology.

[7]  T. Pazina,et al.  Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma , 2018, Front. Immunol..

[8]  Xueda Hu,et al.  Lineage tracking reveals dynamic relationships of T cells in colorectal cancer , 2018, Nature.

[9]  Vincent A. Traag,et al.  From Louvain to Leiden: guaranteeing well-connected communities , 2018, Scientific Reports.

[10]  K. Hargadon,et al.  Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors. , 2018, International immunopharmacology.

[11]  B. Fox,et al.  Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors , 2018, Nature Communications.

[12]  Boxi Kang,et al.  Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing , 2018, Nature Medicine.

[13]  V. Koshkin,et al.  Emerging Role of Immunotherapy in Advanced Urothelial Carcinoma , 2018, Current Oncology Reports.

[14]  J. Cyster,et al.  G-Protein Coupled Receptor 18 Contributes to Establishment of the CD8 Effector T Cell Compartment , 2018, Front. Immunol..

[15]  S. Tomita,et al.  Use of the tumor-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to combination therapy with pertuzumab, trastuzumab, and docetaxel for advanced HER2-positive breast cancer , 2018, Journal of Translational Medicine.

[16]  Julie G. Burel,et al.  Transcriptomic Analysis of CD4+ T Cells Reveals Novel Immune Signatures of Latent Tuberculosis , 2018, The Journal of Immunology.

[17]  H. Joensuu,et al.  Prognostic impact of CD4-positive T cell subsets in early breast cancer: a study based on the FinHer trial patient population , 2018, Breast Cancer Research.

[18]  Allon M Klein,et al.  Single-cell gene expression reveals a landscape of regulatory T cell phenotypes shaped by the TCR , 2018, Nature Immunology.

[19]  Leland McInnes,et al.  UMAP: Uniform Manifold Approximation and Projection for Dimension Reduction , 2018, ArXiv.

[20]  Fabian J Theis,et al.  SCANPY: large-scale single-cell gene expression data analysis , 2018, Genome Biology.

[21]  He Li,et al.  CXCL13 expression is prognostic and predictive for postoperative adjuvant chemotherapy benefit in patients with gastric cancer , 2018, Cancer Immunology, Immunotherapy.

[22]  R. Bourgon,et al.  TGF-β attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells , 2018, Nature.

[23]  Bjoern Peters,et al.  Precursors of human CD4+ cytotoxic T lymphocytes identified by single-cell transcriptome analysis , 2018, Science Immunology.

[24]  J. Marsal,et al.  Colorectal cancer-infiltrating T lymphocytes display a distinct chemokine receptor expression profile , 2017, European Journal of Medical Research.

[25]  Hannah A. Pliner,et al.  Reversed graph embedding resolves complex single-cell trajectories , 2017, Nature Methods.

[26]  J. Lunceford,et al.  IFN-&ggr;–related mRNA profile predicts clinical response to PD-1 blockade , 2017, The Journal of clinical investigation.

[27]  D. Larsimont,et al.  CXCL13-producing TFH cells link immune suppression and adaptive memory in human breast cancer. , 2017, JCI insight.

[28]  J. Utikal,et al.  Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer , 2017, Nature.

[29]  Charles H. Yoon,et al.  An immunogenic personal neoantigen vaccine for patients with melanoma , 2017, Nature.

[30]  Boxi Kang,et al.  Landscape of Infiltrating T Cells in Liver Cancer Revealed by Single-Cell Sequencing , 2017, Cell.

[31]  Christina S. Leslie,et al.  Chromatin states define tumor-specific T cell dysfunction and reprogramming , 2017, Nature.

[32]  H. Stunnenberg,et al.  Transcriptional Landscape of Human Tissue Lymphocytes Unveils Uniqueness of Tumor-Infiltrating T Regulatory Cells , 2016, Immunity.

[33]  G. Plitas,et al.  Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer. , 2016, Immunity.

[34]  Jefte M. Drijvers,et al.  Clonal expansion of CD4(+) cytotoxic T lymphocytes in patients with IgG4-related disease. , 2016, The Journal of allergy and clinical immunology.

[35]  P. Klenerman,et al.  MAIT cells: new guardians of the liver , 2016, Clinical & translational immunology.

[36]  Grace X. Y. Zheng,et al.  Massively parallel digital transcriptional profiling of single cells , 2016, Nature Communications.

[37]  Charles H. Yoon,et al.  Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq , 2016, Science.

[38]  J. Taube,et al.  The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder , 2016, Oncoimmunology.

[39]  P. Campbell,et al.  Somatic mutation in cancer and normal cells , 2015, Science.

[40]  Mikhail Shugay,et al.  MiXCR: software for comprehensive adaptive immunity profiling , 2015, Nature Methods.

[41]  D. Schadendorf,et al.  Nivolumab in previously untreated melanoma without BRAF mutation. , 2015, The New England journal of medicine.

[42]  H. Kohrt,et al.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.

[43]  P. Hegde,et al.  MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer , 2014, Nature.

[44]  J. Cyster,et al.  GPR18 is required for a normal CD8αα intestinal intraepithelial lymphocyte compartment , 2014, The Journal of experimental medicine.

[45]  R. Emerson,et al.  PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.

[46]  Bjoern Peters,et al.  Transcriptional Profile of Tuberculosis Antigen–Specific T Cells Reveals Novel Multifunctional Features , 2014, The Journal of Immunology.

[47]  Claudia C. Preston,et al.  The Ratios of CD8+ T Cells to CD4+CD25+ FOXP3+ and FOXP3- T Cells Correlate with Poor Clinical Outcome in Human Serous Ovarian Cancer , 2013, PloS one.

[48]  J. Wolchok,et al.  Enhancement of Tumor-Reactive Cytotoxic CD4+ T-cell Responses after Ipilimumab Treatment in Four Advanced Melanoma Patients , 2013, Cancer Immunology Research.

[49]  Benjamin Haibe-Kains,et al.  CD4⁺ follicular helper T cell infiltration predicts breast cancer survival. , 2013, The Journal of clinical investigation.

[50]  M. Tremblay,et al.  Exon Level Transcriptomic Profiling of HIV-1-Infected CD4+ T Cells Reveals Virus-Induced Genes and Host Environment Favorable for Viral Replication , 2012, PLoS pathogens.

[51]  A. Vlantis,et al.  CXCR6 and CCR5 localize T lymphocyte subsets in nasopharyngeal carcinoma. , 2012, The American journal of pathology.

[52]  D. Adams,et al.  T lymphocyte recruitment into renal cell carcinoma tissue: a role for chemokine receptors CXCR3, CXCR6, CCR5, and CCR6. , 2012, European urology.

[53]  J. Moyer,et al.  Human TH17 Cells Are Long-Lived Effector Memory Cells , 2011, Science Translational Medicine.

[54]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[55]  A. Krensky,et al.  Biology and clinical relevance of granulysin. , 2009, Tissue antigens.

[56]  P. Sharma,et al.  CTLA-4 blockade increases IFNγ-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients , 2008, Proceedings of the National Academy of Sciences.

[57]  Joshua M. Korn,et al.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.

[58]  B. Kavanagh,et al.  CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion. , 2008, Blood.

[59]  Gerd Ritter,et al.  Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[60]  N. Kedersha,et al.  Characterization of GMP-17, a granule membrane protein that moves to the plasma membrane of natural killer cells following target cell recognition. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[61]  Cheng Li,et al.  Adjusting batch effects in microarray expression data using empirical Bayes methods. , 2007, Biostatistics.